Cancer, General clinical trials at University of California Health
125 in progress, 67 open to eligible people
9-ING-41 in Pediatric Patients with Refractory Malignancies.
open to eligible people ages up to 22 years
9-ING-41 has anti-cancer clinical activity with no significant toxicity in adult patients. This Phase 1 study will study its efficacy in paediatric patients with advanced malignancies.
at UCSF
Biobehavioral Intervention for Latino/Hispanic Young Adults with Cancer
open to eligible males ages 18-39
Building upon the results of a single-arm trial designed to investigate the feasibility and acceptability of a novel intervention, Goal-focused Emotion-Regulation Therapy (GET), this trial is a randomized-controlled biobehavioral pilot trial of GET…
at UC Irvine
Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma
open to eligible people ages 18 years and up
This phase 1/2 trial tests the safety and effectiveness of a cancer vaccine called Labvax 3(22)-23 and GM-CSF alone or in combination with pembrolizumab in treating adenocarcinoma that has spread to other places in the body (advanced stage). Labvax…
at UC Davis
KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
open to eligible people ages 18 years and up
The goal of this clinical trial is to test the safety and efficacy of KVA12123 alone or combined with pembrolizumab in patients with advanced solid tumors. The main questions this study aims to answer are: 1. What is the safety of KVA12123 when…
at UCLA
SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
open to eligible people ages 18 years and up
A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS or EGFR mutations to determine the maximum tolerated dose and recommended Phase II dose of HBI-2376 and characterize its pharmacokinetic profile.
at UCLA
CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
open to eligible people ages 18 years and up
The goal of this clinical trial is to test CPO301, a type of drug called an antibody drug conjugate in adult patients with advanced or metastatic solid tumors. The main questions it aims to answer are: - To assess the safety and tolerability of…
at UCLA
Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
open to eligible people ages 18 years and up
KB707-01 is a Phase 1/2, open-label, multicenter, dose escalation and expansion study. The study will evaluate the safety and tolerability of KB707 in adults with locally advanced or metastatic solid tumors who have progressed on standard of care…
at UCLA
CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors
open to eligible people ages 18 years and up
This is an open-label, dose-escalation, multi-center phase I study evaluating the safety of CF33-hNIS (hNIS - human sodium iodide symporter) administered via two routes of administration, intratumoral (IT) or intravenous (IV), either as a…
at UCSD
Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
“Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”
open to eligible people ages up to 30 years
This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Drugs used in …
at UC Davis UCLA UCSF
SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
open to eligible people ages 18 years and up
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.
at UCLA
A2B694, a Logic-gated CAR T, in Participants with Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
open to eligible people ages 18 years and up
The goal of this study is to test A2B694, an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA),…
at UCLA UCSD
NST-628 Oral Tablets in Subjects With Solid Tumors
open to eligible people ages 18 years and up
This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid …
at UCLA UCSF
Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
open to eligible people ages 18 years and up
The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.
at UCLA
AMXI-5001 for Treatment in Patients With Advanced Malignancies
open to eligible people ages 18 years and up
ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in adult participants with advanced malignancies who have previously failed other therapies. The study has two phases. The purpose of Phase I (Dose Escalation) is to confirm the appropriate…
at UCLA
Abatacept in Immune Checkpoint Inhibitor Myocarditis
open to eligible people ages 18 years and up
The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The…
at UCLA
Financial and Social Needs Among Patients With Cancer
open to eligible people ages 18 years and up
Financial hardship and health-related social needs (e.g., insecurity about food, housing, transportation, utilities) are common among patients with cancer, resulting in health disparities in cancer outcomes. Our study will test the efficacy of a…
at UC Irvine
Biology and Benefits of Music Play and Stories for Kids/Parents During ALL Treatment
open to eligible people ages 3-8
Music therapy has become a standard palliative care service in many pediatric and adult hospitals; however, a majority of music therapy research has focused on the use of music to improve psychosocial dimensions of health, without considering…
at UCSF
ChangeGradients: Promoting Adolescent Health Behavior Change
open to eligible people ages 15-17
As most adolescents visit a healthcare provider once a year, health behavior change interventions linked to clinic-based health information technologies hold significant promise for improving healthcare quality and subsequent behavioral health…
at UCSF
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
open to eligible people ages 18 years and up
The purpose of this study is to compare any good or bad effects of using pembrolizumab (an experimental drug) and radiation therapy (RT), compared to using cisplatin chemotherapy and radiation therapy (RT) in the treatment of patients with head and…
at UCSD
Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
open to eligible people ages 18 years and up
This cluster-randomized comparative effectiveness trial compares a technology-based supportive cancer care (SCC) approach with a redesigned team-based supportive cancer care (SCC) approach.
at UCSF
Whole Body DWI to FDG PET
open to eligible people ages 18 years and up
This is a single arm prospective trial that evaluates whole body diffusion weight imaging (DWI) compared to 18F-fludeoxyglucose (FDG) Positron Emission Tomography with Magnetic resonance imaging (PET/MRI) in participants with known metastatic…
at UCSF
Electroacupuncture for the Management of Symptom Clusters in Cancer Patients and Survivors
open to eligible people ages 16 years and up
This is a sham-controlled, patient and assessor-blinded pilot trial to evaluate the feasibility of administering EA as an intervention for symptom clusters in cancer patients and survivors, and to evaluate the degree that EA could reduce symptom…
at UC Irvine
Electroacupuncture in Symptom Management After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
open to eligible people ages 18 years and up
The investigators are conducting this research study is to evaluate the feasibility (recruitment, compliance, safety, and acceptance) of using electroacupuncture (EA) to manage complex symptoms such as pain, nausea/vomiting, diarrhea, and insomnia…
at UC Irvine
Empowering Hispanic Patients' Lung Cancer Screening Uptake (Empower Latinx)
open to eligible people ages 50-80
The Hispanic/Latinx community (hereafter Hispanic) is the country's second-largest racial/ethnic group, accounting for 19.1% of the total population. However, they remain one of the most underserved populations with suboptimal access to healthcare…
at UC Irvine
Enhancing Lung Cancer Screening Through Human-Centered Intervention
open to eligible people ages 50-80
The purpose of this study is to further understand the factors involved in increasing lung cancer screening.
at UC Davis
Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients
open to eligible people ages 0 months to 50 years
The purpose of this study is to evaluate the effectiveness of a multi-component intervention to improve young cancer survivors' engagement in goal-concordant oncofertility care, concurrently with observing and gathering information on how the…
at UCSD
RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
open to eligible people ages 18 years and up
RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor immunity by increasing endogenous 2'-3'-cyclic guanosine…
at UCLA
Faith in Action! A Church-Based Navigation Model to Increase Breast Cancer Screening in Korean Women
open to eligible females ages 45-80
The purpose of this research is to develop a culturally adapted "Faith in Action!" curriculum to train lay health navigators to provide breast cancer screening navigation to Korean American women within faith-based settings and evaluate whether the…
at UCLA
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
open to eligible people ages 18 years and up
OKI-219-101 is a Phase 1a/1b, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of OKI-219 as monotherapy and in combination with fulvestrant or…
at UCLA UCSD
Imaging of Solid Tumors Using FAP-2286
open to eligible people ages 18 years and up
This is a multi-arm prospective trial that evaluates the ability of a novel imaging radiolabeled agents to detect metastatic cancer in participants with solid tumors using a gallium 68 (68Ga-) or copper 64 (64Cu-) FAP-2286 tracer. FAP-2286 is a…
at UCSF
Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study
open to eligible people ages 45-80
This clinical trial evaluates the usefulness of using a smartphone-based HIV-specific smoking cessation intervention at the time of lung cancer screening in helping people living with HIV quit smoking. Positively Smoke Free - Mobile may help…
at UCSD
Improving Cognition and Behavior in Pediatric Cancer Survivors Using a Novel Mindful Attention Training
open to eligible people ages 7-17
This pilot study will evaluate the cognitive and behavioral outcomes of using a novel, adaptive attention training in pediatric cancer survivors.
at UCSF
Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Pediatric Brain Tumors
open to eligible people ages 1-38
This phase I trial tests the safety, side effects, and best dose of ex vivo expanded natural killer cells in treating patients with cancerous (malignant) tumors affecting the upper part of the brain (supratentorial) that have come back (recurrent)…
at UCSF
Locally AblatiVe TherApy in OLigO-pRogressive SOlid TUmorS (VALOROUS)
open to eligible people ages 18 years and up
This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time …
at UC Davis
Mobile App to Help Survivors of Childhood Cancer Navigate Long-Term Follow-Up Care
open to all eligible people
This clinical trial studies the effectiveness of a newly developed survivorship mobile application (app) designed for survivors, or their caregivers, of childhood cancer to help them better navigate long-term follow-up care. The survivorship app…
at UCSF
Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas
open to eligible people ages 18 years and up
This is a Phase I study to evaluate the safety and efficacy of the [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G theranostics pair in patients with metastatic cancer.
at UC Davis
Implementation of COMPRENDO
open to eligible people ages 18 years and up
COMPRENDO (ChildhOod Malignancy Peer Research NavigatiOn) is a multi-site randomized clinical trial (RCT) that uses a Hybrid Type 1 design, to test the effects of a clinical intervention on patient-level outcomes, while exploring multilevel…
at UCSD UCSF
National Liver Cancer Screening Trial
open to eligible people ages 18-85
The National Liver Cancer Screening Trial is an adaptive randomized phase IV Trial comparing ultrasound-based versus biomarker-based screening in 5500 patients with cirrhosis from any etiology or patients with chronic hepatitis B infection. Eligible …
at UCSF
Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
open to eligible people ages 18 years and up
TRE-515 is a first-in-class small molecule inhibitor of deoxycytidine kinase (dCK) that is being developed for oral administration in patients with solid tumors. In cancer cells, rapid and upregulated DNA replication creates high replication stress, …
at UCLA
Pan Tumor Rollover Study
open to eligible people ages 18 years and up
Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
at UCSF
MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
open to eligible people ages 18 years and up
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.
at UC Irvine UCSD
Preoperative Immunotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck
open to eligible people ages 18 years and up
To determine the effect of neoadjuvant atezolizumab alone or in combination with other immune modulating agents on T-cell infiltration in advanced SCCHN. To determine the impact of neo-adjuvant immunotherapy on surgical outcomes.
at UCSF
FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
open to eligible people ages 18 years and up
This exploratory study investigates how an imaging technique called 68Ga-FAPi-46 PET/CT can determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues in patients with cancer. Because some cancers…
at UCLA
RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy
open to eligible people ages 30 months to 18 years
Chemotherapy-induced nausea and vomiting (CINV) are among the most bothersome symptoms during cancer treatment according to children and their parents. Most children receiving highly emetogenic chemotherapy (HEC), including those receiving…
at UCSF
PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
open to eligible people ages 18 years and up
This is a first-in-human (FIH), open label Phase 1/1b / Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment. Phase 1 will identify potential optimal biologically relevant doses (OBRD) and the maximum…
at UCSF
Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
open to eligible people ages 18 years and up
Study CJB-101-01 will be conducted at multiple centers in the USA and Republic of Korea as an open-label safety and preliminary efficacy study of CJRB-101 in combination with pembrolizumab in subjects with selected types of advanced or metastatic…
at UC Irvine UCSF
AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
open to eligible people ages 18 years and up
The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.
at UCLA
Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
open to eligible people ages 18 years and up
This study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have been previously untreated.
at UCSF
Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
open to eligible males ages 18 years and up
This is a multicenter, single-arm, two-stage open-label phase 2 study of the combination of cabozantinib + nivolumab in subjects with advanced castration-resistant prostate cancer (CRPC).
at UCSD
INKmune in Patients With mCRPC (CaRe Prostate)
open to eligible males ages 18 years and up
This is an open-label, phase I/IIa dose escalation and expansion study of INKmune in men with mCRPC. INKmune is administered to patients intravenously over three doses, at least one-week apart. The study will consist of two stages.
at UCLA
Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
open to eligible males ages 18 years and up
Phase 2 open-label, single-arm clinical trial evaluating the efficacy and safety of neoadjuvant olaparib + LHRH agonist administered for 6 months prior to radical prostatectomy (RP) in men with unfavorable intermediate-risk or high-risk localized…
at UCSD
RP1 Monotherapy and RP1 in Combination With Nivolumab
open to eligible people ages 18 years and up
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and…
at UC Irvine UCLA UCSD UCSF
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
“What is the best mammogram screening schedule for women? Clinical experts disagree. Help us find out!”
open to eligible females ages 30-74
Most physicians still use a one-size-fits-all approach to breast screening in which all women, regardless of their personal history, family history or genetics (except BRCA carriers) are recommended to have annual mammograms starting at age 40.…
at UC Davis UC Irvine UCLA UCSD UCSF
Tobacco Cessation Care for Cancer Patients by Automated Interactive Outreach
open to eligible people ages 18 years and up
This is a multi-arm, randomized controlled, pilot study which will recruit cancer patients who have been seen by a UCSF Cancer Center-affiliated clinical department to evaluate the efficacy of "CareConnect". This is the first study to assess the…
at UCSF
DFP-14927 in Advanced Solid Tumors
open to eligible people ages 18 years and up
This is a Phase I, open-label, single-arm, dose escalation study of DFP-14927 intravenous infusion administered to patients with refractory or relapsed solid tumors.
at UCLA
UCSD Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases
open to eligible people ages 18 years and up
In this proposal, the investigators introduce advanced diffusion and volumetric imaging techniques along with innovative, automated image parcellation methods to identify critical brain regions, incorporate into cognitive-sparing SRS, and analyze…
at UCSD
Utilizing Advocates and Supporters to Increase Lung Cancer Screening Rates in Eligible Participants
open to eligible people ages 40-80
This clinical trial assesses the use of advocates and supporters of breast and lung cancer screening to increase lung cancer screening rates amongst eligible participants. Imaging-based cancer screening is utilized with variable frequency. Breast…
at UCLA
Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
open to eligible people ages 18 years and up
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens presented on specific Human…
at UCSD
Biomarkers for Risk Stratification in Lung Cancer
open to eligible people ages 40 years and up
This is a prospective observational study that will follow patients who undergo lung cancer screening at the San Francisco VA Medical Center, University of California, San Francisco (UCSF) Medical Center, and the San Francisco General Hospital. The…
at UCSF
Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure
open to eligible people ages 13-39
Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) are commonly given to treat pediatric cancer, and carry a risk of cardiotoxicity. Over the long term, children who receive these therapies have an increased risk of heart failure and…
at UCSD
Childhood Cancer Survivor Study
open to all eligible people
The Childhood Cancer Survivor Study (CCSS) will investigate the long-term effects of cancer and its associated therapies. A retrospective cohort study will be conducted through a multi-institutional collaboration, which will involve the…
at UC Irvine UCLA UCSF
Discovering Cancer Risks From Environmental Contaminants and Maternal/Child Health
open to eligible people ages 18 years and up
The DREAM Cohort is a longitudinal observational study developed to enhance our understanding of how multiple exposures to environmental chemicals and pollutants across a diverse population of pregnant women and their offspring are linked to cancer…
at UCSF
Fatigue and Molecular Mechanisms in Cancer Patients Receiving CCRT
open to eligible people ages 18 years and up
Cancer-related fatigue (CRF) is a significant problem for cancer patients. This prospective, basic science, observational study will evaluate for changes in CRF associated with molecular characteristics prior to, during, and at the completion of…
at UCSF
Pancreatic Cancer Screening
open to eligible people ages 18 years and up
This study investigates how often abnormal findings from routine magnetic resonance imaging occur in people with genetic mutations in BReast CAncer gene. (BRCA), ataxia telangiectasia mutated gene (ATM), or PALB2 screened for pancreatic cancer. This …
at UCSF
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
open to eligible people ages 18 years and up
Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make…
at UCLA UCSD
Personalized Cancer Therapy to Determine Response and Toxicity
open to eligible people ages 7 years and up
The purpose of this study is to learn more about personalized cancer therapy including response to treatment and side effects. Information about the tests and treatments a person received, or will receive, for their cancer will be collected from…
at UCSD
Targeted Therapy to Increase RAI Uptake in Metastatic DTC
open to eligible people ages 0 years and up
Papillary thyroid cancer (PTC) is a common type of differentiated thyroid cancer (DTC) in children and represents the second most common cancer in adolescent females. Recently targeted drugs that block many of the genetic drivers of DTC have become…
at UCSF
(Peak) a Phase 3 Randomized Trial of CGT9486+Sunitinib Vs. Sunitinib in Subjects with Gastrointestinal Stromal Tumors
Sorry, not currently recruiting here
This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 442 patients. Part 1 consists of two evaluations: 1) confirming the dose of an…
at UCLA UCSD UCSF
9-ING-41 in Patients with Advanced Cancers
Sorry, in progress, not accepting new patients
GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic…
at UC Irvine UCSF
Novel Method for Treating Lung Met W/Combo of Electric Fields & Rad Therapy: a Single-Arm
Sorry, in progress, not accepting new patients
This is a phase 0, pilot prospective study to determine the feasibility of combined irreversible electroporation (IRE) and radiation therapy in subjects with lung tumors with metastatic cancer of any histology. These are subjects who have advanced…
at UC Irvine
Firi-cel in Patients with Relapsed/refractory Large B-cell Lymphoma
Sorry, in progress, not accepting new patients
This is a prospective, open-label, multi-center clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of firicabtagene autoleucel (firi-cel), a CD22-directed autologous…
at UCLA
Comparing Two Types of Supportive Interventions for Caregivers of Patients With Cancer
Sorry, in progress, not accepting new patients
The purpose of this study is to compare two types of therapy for caregivers of cancer patients: Emotion Regulation Therapy for Cancer Caregivers (ERT-C) and Cognitive Behavioral Therapy (CBT-C). The researchers want to see if ERT-C is better than,…
at UC Irvine
Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
Sorry, in progress, not accepting new patients
This is an open-label, multicenter, non-randomized extension and long-term observational study. Participants receiving atezolizumab monotherapy or atezolizumab combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored…
at UCLA
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
Sorry, in progress, not accepting new patients
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from …
at UCSD UCSF
Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Sorry, in progress, not accepting new patients
The main purpose of this study is to evaluate the efficacy and safety of ramucirumab or merestinib or placebo plus cisplatin and gemcitabine in participants with advanced or metastatic biliary tract cancer.
at UCSF
Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer
Sorry, in progress, not accepting new patients
The main objective for part 1a of the study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) and to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of oral TACH101 in participants with…
at UC Irvine
A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Sorry, not currently recruiting here
The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC),…
at UCLA UCSD
A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
Sorry, in progress, not accepting new patients
The goal of this study is to test A2B530,an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), and other solid tumors that…
at UCLA UCSD
LYL797 in Adults With Solid Tumors
Sorry, in progress, not accepting new patients
This study will evaluate the safety and tolerability of LYL797, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), platinum-resistant epithelial …
at UCLA
Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
Sorry, in progress, not accepting new patients
The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.
at UCLA
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Sorry, not currently recruiting here
To assess: - efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors…
at UCSF
Assessment Tool for Older Patients With Cancer
Sorry, in progress, not accepting new patients
RATIONALE: A study that assesses the ability of older patients to think, learn, remember, make judgments, and carry out daily activities may help doctors plan treatment for older patients with cancer. PURPOSE: This clinical trial is studying an…
at UC Irvine
Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease
Sorry, in progress, not accepting new patients
The purpose of this study is to determine whether stereotactic body radiation therapy (SBRT) combined with checkpoint blockaded immunotherapy (CBI) will improve the response to the anticancer treatment compared to CBI alone in patients with advanced …
at UCSD
Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma
Sorry, in progress, not accepting new patients
This is a 2 strata pilot trial within the Pacific Pediatric Neuro-Oncology Consortium (PNOC). The study will use a new treatment approach based on each patient's tumor gene expression, whole-exome sequencing (WES), targeted panel profile (UCSF 500…
at UCSD UCSF
TheraSphere Prostate Cancer (PCa) Device
Sorry, not currently recruiting here
The VOYAGER Study is an interventional, non-randomized, single-arm, dose escalation trial with the goal of determining the safety of TheraSphere PCa device in patients with clinically localized prostate cancer across US-based centers.
at UCLA
Empowering Patients' Lung Cancer Screening Uptake
Sorry, in progress, not accepting new patients
Lung cancer is the leading cause of cancer related mortality. Lung cancer screening (LCS) with low dose computed tomography (LDCT) decreases mortality rate of lung cancer by 20%. Yet many patients who are eligible for lung cancer screening are still …
at UC Irvine
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
Sorry, in progress, not accepting new patients
This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) profiles of a novel fragment crystallizable (Fc)-engineered immunoglobulin G1 anti-cytotoxic T-lymphocyte…
at UCLA
Head to Head Trial of Mailed Cologuard to Mailed FIT
Sorry, accepting new patients by invitation only
The objective of this study is to measure the comparative effectiveness of mailed outreach of two stool based tests, multi-target stool DNA (Cologuard) and the fecal immunochemical test (FIT) in screening eligible adults ages 45-49 receiving care at …
at UCSD
Artificial Intelligence on Breast Cancer Screening
Sorry, not yet accepting patients
The goal of this clinical trial is to compare patient-centered outcomes when 3D screening mammograms are interpreted with versus without a leading FDA-cleared AI decision-support tool in real-world U.S. settings and to assess patient's perspectives…
at UCLA
Implementation Research to Increase Colorectal Cancer Screening Rates Among Low Income and Ethnic Minority Groups
Sorry, in progress, not accepting new patients
This clinical trial implements research strategies to increase colorectal cancer (CRC) screening rates among low income and ethnic minority groups. CRC is the second most common cause of cancer mortality in the United States and disproportionately…
at UCLA
Interactive Mobile Doctor (iMD) to Promote Tobacco Cessation Among Cancer Patients
Sorry, in progress, not accepting new patients
The proposed pilot study aims to develop and test a patient video educational tool, an interactive Mobile Doctor (iMD), that can be integrated in radiation oncology setting to effectively engage cancer patients receiving treatment at University of…
at UCSF
Intervening on Women's Health for Rural Young Cancer Survivors
Sorry, not currently recruiting here
The purpose of this pilot study is to evaluate the feasibility of a multi-component intervention to improve young female cancer survivors' engagement in goal-concordant reproductive health care. The investigators hypothesize that implementation of…
at UCSD
Intervention Development and Evaluation to Reduce Disparities in Quality of Life for Latino Families Impacted by Cancer
Sorry, in progress, not accepting new patients
The purpose of this study is to determine if a culturally relevant caregiver intervention is effective in decreasing stress and improving quality of life in Spanish speaking Latino caregivers of children diagnosed with cancer compared to a control…
at UC Irvine
Lung Cancer Screening CT for Firefighters
Sorry, not yet accepting patients
Firefighters are at increased risk for cancer due to exposure to carcinogenic substances. Current lung cancer screening guidelines are predominantly based on smoking history and do not take into account high risk occupational exposures such as…
at UCSF
Ovarian Reserve Testing in Female Young Adult Cancer Survivors
Sorry, in progress, not accepting new patients
Young adult cancer survivors constitute an under served population to whom fertility potential is particularly important. For female young adult patients, cancer treatment such as alkylating chemotherapy are toxic to the finite number of eggs they…
at UCSD
Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers
Sorry, in progress, not accepting new patients
The purpose of this study is to determine if it is possible to make and administer safely a 'personalized' vaccine to treat patients that have been diagnosed with advanced cancer and are not candidates for curative therapy.
at UCSD
LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy
Sorry, in progress, not accepting new patients
LVGN6051 is a humanized monoclonal antibody that specifically binds to CD137, and acts as an agonist against CD137. This first in human study of LVGN6051 is designed to establish the maximum tolerated dose (MTD) and/or the recommended dose for…
at UC Irvine UCSF
Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
Sorry, in progress, not accepting new patients
A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes
at UCLA UCSF
Researching the Effect of Aerobic Exercise on Cancer
Sorry, in progress, not accepting new patients
This study is being done to answer the following question: Will aerobic exercise (exercise that stimulates and strengthens the heart and lungs, and improves the body's use of oxygen) change the biomarkers (signs of disease) found in the blood?
at UCLA
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab
Sorry, accepting new patients by invitation only
The rationale of the ROSY-D study is to continue to provide study treatment for patients who have participated in a parent study with Durvalumab and who are continuing to derive clinical benefit from treatment at the end of such studies, as judged…
at UCLA
Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.
Sorry, not yet accepting patients
The purpose of this study is to compare whether the FDA and Health Canada approved microUS is as effective as the currently used option (MRI) for imaging the prostate gland. Participants will be randomized into two groups to compare the imaging…
at UCLA
Screening With a DNA Blood Test to Address Colorectal Cancer Inequities
Sorry, accepting new patients by invitation only
Colorectal cancer (CRC) screening participation is suboptimal and associated with inequities in CRC outcomes by race/ethnicity and socioeconomic position. A novel, cell free DNA (cfDNA) blood test has potential to increase participation, but has not …
at UCSD
ART0380 in Patients With Biologically Selected Solid Tumors
Sorry, in progress, not accepting new patients
This interventional study will evaluate the efficacy and safety of ART0380 as monotherapy in patients whose tumors have a biology to predict for sensitivity to inhibition of Ataxia-Telangiectasia Mutated and Rad3-related protein kinase (ATR).
at UCLA
Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients
Sorry, in progress, not accepting new patients
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with adagrasib in patients with G12C Non-Small Cell Lung Cancer (NSCLC) who have been exposed to prior G12C inhibitor and experienced progressive disease.
at UCSF
BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
Sorry, in progress, not accepting new patients
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL.
at UC Davis UC Irvine UCLA
Cabozantinib Plus TAS102 in mCRC as Salvage Therapy
Sorry, in progress, not accepting new patients
This is a phase I clinical trial assessing the safety and recommended phase II dose of cabozantinib in combination with trifluridine/tipiracil (TAS102) in patients with metastatic colorectal carcinoma (mCRC).
at UC Irvine
EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
Sorry, in progress, not accepting new patients
This is a multicenter, open-label, phase I/II basket study, evaluating the safety, tolerability, RP2D, pharmacokinetics, pharmacodynamics and antitumor activity of EOS-448 (also known as GSK4428859A or belrestotug) combined with standard of care…
at UCSD
NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)
Sorry, in progress, not accepting new patients
This is a phase 1a/1b, multicentre, open-label, non-randomized study of NG-350A in combination with pembrolizumab in patients with metastatic or advanced epithelial tumours.
at UCLA
Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
Sorry, in progress, not accepting new patients
This study will examine the combination of pembrolizumab and tadalafil for safety and efficacy in advanced head and neck cancer.
at UCSD
Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
Sorry, in progress, not accepting new patients
Funding Source - FDA OOPD FDA-approved products for patients with unresectable or metastatic GIST include therapies such as imatinib and sunitinib. Although there are FDA-approved products for the treatment of advanced/metastatic GIST, these…
at UCSD
PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Sorry, not currently recruiting here
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1…
at UC Irvine UCLA UCSF
Treating Pain in Children With Cancer: Pain Buddy
Sorry, in progress, not accepting new patients
The purpose of this study is to examine the feasibility of the ambulatory monitoring protocol, called Pain Buddy, in documenting children's pain, symptoms and quality of life while receiving outpatient chemotherapy. The long term goal of Pain Buddy…
at UC Irvine
UC Health Care Planning Study
Sorry, in progress, not accepting new patients
Using a cluster randomized design at the clinic level, this project will implement and test three real-world, scalable advance care planning interventions among primary care clinics across three University of California health systems. Seriously ill …
at UC Irvine UCLA UCSF
UCLA Health Patient Health Maintenance Outreach Text Message
Sorry, in progress, not accepting new patients
This is a prospective randomized clinical trial evaluating how behaviorally-informed outreach text messages impact patient engagement with primary care. This prospective randomized control trial is being implemented in conjunction with UCLA Health's …
at UCLA
UCLA Health Patient Health Maintenance Text Reminder
Sorry, in progress, not accepting new patients
This is a prospective randomized clinical trial evaluating how behaviorally-informed outreach text message reminders impact patient engagement with primary care. This prospective randomized control trial is being implemented in conjunction with UCLA …
at UCLA
UCLA Health Patient Health Maintenance Text Reminder July 2023
Sorry, in progress, not accepting new patients
This is a prospective randomized clinical trial evaluating how behaviorally-informed outreach text message reminders impact patient engagement with primary care. This prospective randomized control trial is being implemented in conjunction with UCLA …
at UCLA
UCLA Health Patient Health Maintenance With Interactive Text Reminder
Sorry, in progress, not accepting new patients
This is a prospective randomized clinical trial evaluating how behaviorally-informed outreach text message reminders impact patient engagement with primary care. This prospective randomized control trial is being implemented in conjunction with UCLA …
at UCLA
Assessing Reproductive Outcomes in Young Female Cancer Survivors Through a National Fertility Preservation Registry
Sorry, in progress, not accepting new patients
The FIRST project is a national fertility preservation registry for young women facing cancer treatments. The investigators will examine how different cancers and treatments affect the reproductive health of young survivors. This prospective cohort…
at UCSD
Colorectal Cancer Screening in Cystic Fibrosis
Sorry, in progress, not accepting new patients
This multi-center study will compare multi-target DNA and quantitative FIT stool-based testing to colonoscopy in individuals with Cystic Fibrosis (CF) undergoing colon cancer screening with colonoscopy. The primary endpoint is detection of any…
at UCLA
Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)
Sorry, not accepting new patients
This is an expanded access study for cancer treatment with balstilimab alone or in combination with zalifrelimab for an intermediate-size participant population. This study addresses the treatment needs of participants who have been previously and…
at UCSF
Master Rollover Protocol for Continued Safety Assessment of Study Drug
Sorry, not accepting new patients
This study is for patients who have participated in a previous study and who continue to receive benefit to have continued access to study drug and/or treatment.
at UCLA
Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study
Sorry, not currently recruiting here
This study investigates ways to detect prostate cancer earlier in people at genetic risk for disease that forms, grows, or spreads quickly (aggressive). Studying samples of blood, urine, and/or tissue in the laboratory may help doctors further…
at UCSF
Serial PET MPI in Patients Undergoing Cancer Treatment
Sorry, accepting new patients by invitation only
This study aims to evaluate the effects of cardiotoxic cancer therapies on myocardial blood flow (MBF) and perfusion in a prospective sample of VA patients.
at UCLA
Vallania Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening
Sorry, in progress, not accepting new patients
This protocol is a case-control, multicenter, diagnostic study to collect blood samples to support the development of blood-based screening tests for multiple cancers.
at UC Davis
Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC
Sorry, in progress, not accepting new patients
This study is being done to understand how many people with HIV (PWH) present for cancer care across the AIDS Malignancy Consortium in the United States and if there are reasons that some PWH choose to participate, or not in cancer clinical trials.…
at UCSD
Our lead scientists for Cancer, General research studies include Pamela Munster Jeremy Harris Mehrdad Arjomandi, M.D. Oliver Eng, MD Noah C. Federman, MD Jacqueline Casillas, MD Gregory Daniels, MD, PhD Michael A Hoyt, PhD Janice Tsoh Shumei Kato, MD Andrew Ko Julie L Sutcliffe Varun Monga Moon Chen, M.P.H, Ph.D Alain Algazi Zev A. Wainberg, MD Jae Ho Sohn, MD, MS Thomas Hope Gelareh Sadigh Jonathan Goldman, MD Rana R. McKay, MD Adam Burgoyne, MD, PhD Matthew Cooperberg, MD, MPH Grant Turner, MD Peggy Reynolds, PhD Rene Packard, MD, PhD Ashley E. Prosper, MD Eric H. Yang, MD Jennifer Michlitsch, MD Sabine Mueller Robert Goldsby, MD Richard K. Leuchter, MD Jeremie Calais Laura Esserman, MD, MBA Jason Sicklick, MD Farshid Dayyani Erin Reid, MD Tianhong Li Aditya Bardia, MPH, MBBS Joaquin Anguera, PhD Joseph Califano Joshua Demb, PhD, MPH Elizabeth Ozer, PhD Loren Mell, MD Sue Yom, MD Christopher Dvorak Neil S Wenger, MD Hari Narayan, MD Bartosz Chmielowski, MD, PhD Marla D. Lipsyc-Sharf, MD Andrew Sharabi, MD, PhD Deborah J. Wong, MD, PhD Jona Hattangadi-Gluth, MD Xiao Zhao, MD Sandip Patel, MD Lee S. Rosen, MD J. Randolph Hecht, MD Matthew B. Rettig, MD Alexandre Chan, PharmD Neil Mehta, MD.
Last updated: